Prime Highlights
- Pfizer’s Q2 2025 EPS jumped to $0.78, above consensus and powering more than 5% stock increases.
- The company increased full-year adjusted EPS targets to $2.90–$3.10 with revenue targets remaining at $61B–$64B.
Key Fact
- Pfizer announced second-quarter revenue of about $14.7 billion, up by 10% versus the previous-year quarter, based on strong sales of some of its flagship products.
- The firm seeks to achieve $7.2 billion in savings in expenses by 2027 to make investments towards long-term profitability.
Key Background
In the second quarter of 2025, Pfizer recorded revenues of about $14.7 billion, up 10% operation from the previous year. Earnings per share are more at $0.78, well above estimates of about $0.58. Net income increased to $2.91 billion, more than $41 million for the comparable period last year, which is a positive sign of operating gains and improved product performance.
Revenue growth was driven by top-selling items such as Vyndaqel for cardiovascular disease, Comirnaty (COVID-19 vaccine), Paxlovid (antiviral medication), Padcev for cancer, and blood thinner Eliquis. Sales of Comirnaty doubled to $381 million, while Paxlovid increased 70% to $427 million, both of which also beat market estimates. The growth shows the strength of Pfizer’s diversified portfolio beyond COVID drugs.
Pfizer’s continued cost-cutting effort remains the core of its financial strategy. The company kept its $7.2 billion 2027 net cost reduction target intact through operational leverage and R&D and administrative cost reductions, decreasing around 8–9% in the quarter. The effective tax rate also moved directionally to 13%, supporting profitability and driving margin growth.
Looking forward, Pfizer increased its full-year adjusted EPS forecast to $2.90–$3.10 and kept revenue estimates at $61B–$64B on the expectation of conservative estimates for COVID-driven sales in the fourth quarter of the year. Apart from political and regulatory pushback against drug pricing and worry about possible tariffs, Pfizer emphasized its wide U.S. base of manufacturing as a hedge against such pressures.
Overall, Pfizer Q2 is an example of effective execution, cost control, and diversified product portfolio. Earnings beat and better profit visibility are a reflection of the company’s strength in being able to counter industry headwinds to generate sustained value to shareholders.
Read Also : Celsius Energy Drink Cans Recalled After Being Found Containing Alcohol
